Vedolizumab Does Not Affect Antibody Secreting Cell Recruitment to the Lactating Mammary Gland of Mothers With Inflammatory Bowel Disease

Josef Urrete; Taniya Mitra; Brigid S Boland; Kerri Bertrand; Christina Chambers; Jesús Rivera-Nieves

doi:10.1093/ibd/izae023

Vedolizumab Does Not Affect Antibody Secreting Cell Recruitment to the Lactating Mammary Gland of Mothers With Inflammatory Bowel Disease

Inflamm Bowel Dis. 2024 Feb 9:izae023. doi: 10.1093/ibd/izae023. Online ahead of print.

Authors

Josef Urrete¹, Taniya Mitra^{1

2}, Brigid S Boland¹, Kerri Bertrand³, Christina Chambers³, Jesús Rivera-Nieves^{1

2}

Affiliations

¹ Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
² GI Section, San Diego VA Medical Center (SDVAMC), San Diego, CA, USA.
³ Department of Pediatrics, Division of Environmental Science and Health, University of California San Diego, La Jolla, CA, USAñ.

PMID: 38334263
DOI: 10.1093/ibd/izae023

No abstract available

Keywords: IgA; integrins; lactation; vedolizumab.

Plain language summary

Despite a known role for α4β7 and MAdCAM-1 for the recruitment of antibody secreting cells to the lactating mammary gland, vedolizumab which targets integrin α4β7 did not lower breastmilk IgA in lactating mothers with IBD receiving the drug. It is likely that antibody secreting cells alternatively employ α4β1 to arrest on VCAM-1 also expressed by the lactating mammary gland.

Plain language summary

Grants and funding